Asia Pacific Lung Cancer Screening Market Forecast to 2030

Asia Pacific Lung Cancer Screening Market Forecast to 2030 – Regional Analysis – by Cancer Type [Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer], Technology [Low-Dose Computed Tomography (LDCT), Chest X-Ray, Liquid Biopsy, and Others], Age Group (50 & Older and Below 50), and End User (Hospitals, Diagnostic Centers, and Others)

Send Enquiry
Item ID: BMIRE00029045 Category: Tags: , ,

$2,100$3,500

Description

The Asia Pacific lung cancer screening market is expected to grow from US$ 711.20 million in 2022 to US$ 1,362.43 million by 2030. It is estimated to grow at a CAGR of 8.5% from 2022 to 2030.

Structured Lung Cancer Screening Program Fuel Asia Pacific lung Cancer Screening Market
Several countries face challenges with lung cancer screening programs. A few examples of population-based Australian screening programs are “BreastScreen,” the “National Bowel Cancer Screening Program,” and the “National Cervical Screening Program.”
On behalf of the Ministry of Health, the RIVM Center for Population Screening (RIVM-CvB) leads and manages the National Population Screening Programme; under which all Dutch citizens are invited, at a certain point in their lives, to participate in one of the national screening programs. The State begins, sets up, and finances three cancer population screening programs.
Therefore, there is a crucial requirement for a well-structured program such as a community-based program or a shared, informed decision-making program between clinicians and potential participants; accredited reporting centers; and a central data registry for quality control, monitoring, and outcome reporting. Additionally, integrated smoking cessation intervention, international data supporting cost-effectiveness, additional mortality benefits, and a high sustainability rate are a few factors that must be studied for lung cancer screening. Further, the International Association for the Study of Lung Cancer recommends implementing feasibility screening programs in the countries of Asia Pacific without participating in lung cancer screening studies. These programs involve smoking cessation initiatives, standardized algorithms for selecting and managing screening participants, and specialist multidisciplinary teams to manage participants with positive screening results. Therefore, the implementation of structured lung cancer screening programs is expected to be a lucrative opportunity in the lung cancer screening market during the forecast period.

Asia Pacific Lung Cancer Screening Market Overview

The Asia Pacific lung cancer screening market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and growing prevalence of cigarette smoking among people. Also, rising government support for screening has led to the further growth of the market.

Asia Pacific lung cancer screening market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Lung Cancer Screening Market Segmentation
The Asia Pacific lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.

Based on cancer type, the Asia Pacific lung cancer screening market is segmented into Non–Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer. The non–small cell lung cancer (NSCLC) segment held a larger share of the Asia Pacific lung cancer screening market in 2022.

Based on technology, the Asia Pacific lung cancer screening market is segmented into chest x-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Chest x-ray segment held the largest share of the Asia Pacific lung cancer screening market in 2022.

Based on age group, the Asia Pacific lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the Asia Pacific lung cancer screening market in 2022.

Based on end user, the Asia Pacific lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the Asia Pacific lung cancer screening market in 2022.

Based on country, the Asia Pacific Lung Cancer Screening Market is segmented into China Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific lung cancer screening market in 2022.

Intelerad Medical Systems Incorporated, Nuance Communications Inc, GE HealthCare Technologies Inc, Medtronic Plc, Canon Medical Systems Corp, Koninklijke Philips NV, and Siemens AG are some of the leading companies operating in the Asia Pacific lung cancer screening market.

Summary Info

Industry:

Number of pages:

Pricing options:

, ,

Publishing status:

Geographical coverage:

Year of Publication:

At 8.5% CAGR, the Asia Pacific Lung Cancer Screening Market is speculated to be worth US$ 1,362.43 million by 2030, saysthe research team

According tothe research team’ Research, the Asia Pacific lung cancer screening market was valued at US$ 711.20 million in 2022 and is expected to reach US$ 1,362.43 million by 2030, registering a CAGR of 8.5% from 2022 to 2030. Rising lung cancer incidences and increasing government are the critical factors attributed to the Asia Pacific lung cancer screening market.

Several countries face challenges with lung cancer screening programs. A few examples of population-based Australian screening programs are “BreastScreen,” the “National Bowel Cancer Screening Program,” and the “National Cervical Screening Program.”
On behalf of the Ministry of Health, the RIVM Center for Population Screening (RIVM-CvB) leads and manages the National Population Screening Programme; under which all Dutch citizens are invited, at a certain point in their lives, to participate in one of the national screening programs. The State begins, sets up, and finances three cancer population screening programs.

Therefore, there is a crucial requirement for a well-structured program such as a community-based program or a shared, informed decision-making program between clinicians and potential participants; accredited reporting centers; and a central data registry for quality control, monitoring, and outcome reporting. Additionally, integrated smoking cessation intervention, international data supporting cost-effectiveness, additional mortality benefits, and a high sustainability rate are a few factors that must be studied for lung cancer screening. Further, the International Association for the Study of Lung Cancer recommends implementing feasibility screening programs in the countries of Asia Pacific without participating in lung cancer screening studies. These programs involve smoking cessation initiatives, standardized algorithms for selecting and managing screening participants, and specialist multidisciplinary teams to manage participants with positive screening results. Therefore, the implementation of structured lung cancer screening programs is expected to be a lucrative opportunity in the lung cancer screening market during the forecast period.

On the contrary, high cost of lung cancer screening hampers the Asia Pacific lung cancer screening market.

Based on cancer type, the Asia Pacific lung cancer screening market is segmented into non–small cell lung cancer (NSCLC) and small cell lung cancer. The non–small cell lung cancer (NSCLC) segment held 75.6% share of Asia Pacific lung cancer screening market in 2022, amassing US$ 537.32 million. It is projected to garner US$ 1,012.83 million by 2030 to expand at 8.2% CAGR during 2022–2030.

Based on technology, the Asia Pacific lung cancer screening market is segmented into Chest X-Ray, Low Dose Computed Tomography (LDCT), liquid biopsy, and others. The chest X-Ray segment held 38.9% share of Asia Pacific lung cancer screening market in 2022, amassing US$ 276.82 million. It is projected to garner US$ 528.07 million by 2030 to expand at 8.4% CAGR during 2022–2030.

Based on age group, the Asia Pacific lung cancer screening market is segmented into 50 and Older and Below 50. The 50 and older segment held 89.0% share of Asia Pacific lung cancer screening market in 2022, amassing US$ 632.97 million. It is projected to garner US$ 1,204.30 million by 2030 to expand at 8.4% CAGR during 2022–2030.
Based on end user, the Asia Pacific lung cancer screening market is segmented into hospitals, diagnostic centers, and others. The hospitals segment held 41.6% share of Asia Pacific lung cancer screening market in 2022, amassing US$ 296.00 million. It is projected to garner US$ 545.92 million by 2030 to expand at 8.0% CAGR during 2022–2030.

Based on country, the Asia Pacific lung cancer screening market has been categorized into the China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that the China captured 83.5% share of Asia Pacific lung cancer screening market in 2022. It was assessed at US$ 593.71 million in 2022 and is likely to hit US$ 1,134.08 million by 2030, exhibiting a CAGR of 8.4% during 2022–2030.

Key players operating in the Asia Pacific lung cancer screening market are Intelerad Medical Systems, Nuance Communications Inc, GE HealthCare, Medtronic, Canon Inc, Koninklijke Philips NV, and Siemens AG, among others.

– Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific frozen waffles market.
– Highlights key business priorities in order to assist companies to realign their business strategies.
– the key findings and recommendations highlight crucial progressive industry trends in Asia Pacific frozen waffles market, thereby allowing players across the value chain to develop effective long-term strategies.
– develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
– Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
– Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 Study Scope
1.2 Research Report Guidance
1.3 Market Segmentation
1.3.1 Asia Pacific Lung Cancer Screening Market – by Technology
1.3.2 Asia Pacific Lung Cancer Screening Market – by Cancer Type
1.3.3 Asia Pacific Lung Cancer Screening Market – by Age Group
1.3.4 Asia Pacific Lung Cancer Screening Market – by End User
1.3.5 Asia Pacific Lung Cancer Screening Market – by Country
2. Asia Pacific Lung Cancer Screening Market – Key Takeaways
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Lung Cancer Screening Market – Market Landscape
4.1 Overview
4.2 Asia Pacific PEST Analysis
4.3 Expert’s Opinion
5. Asia Pacific Lung Cancer Screening Market – Key Market Dynamics
5.1 Market Drivers
5.1.1 Rising Lung Cancer Incidences
5.1.2 Increasing Government Support
5.2 Market Restraints
5.2.1 High Cost of Lung Cancer Screening Tests
5.3 Market Opportunities
5.3.1 Structured Lung Cancer Screening Program
5.4 Future Trends
5.4.1 Mobile Lung Cancer Screening Truck
5.5 Impact Analysis
6. Asia Pacific Lung Cancer Screening Market – Asia Pacific Analysis
6.1 Asia Pacific Lung Cancer Screening Market Revenue Forecast and Analysis
7. Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2028 – By Cancer Type
7.1 Overview
7.2 Asia Pacific Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
7.3 Non–Small Cell Lung Cancer (NSCLC)
7.3.1 Overview
7.3.2 Non–Small Cell Lung Cancer (NSCLC): Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Mn)
7.4 Small Cell Lung Cancer
7.4.1 Overview
7.4.2 Small Cell Lung Cancer: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Lung Cancer Screening Market Analysis – by Technology
8.1 Overview
8.2 Low-Dose Computed Tomography (LDCT)
8.2.1 Overview
8.2.2 Low-Dose Computed Tomography (LDCT): Asia Pacific Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.3 Chest X-ray
8.3.1 Overview
8.3.2 Chest X-ray: Asia Pacific Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.4 Liquid Biopsy
8.4.1 Overview
8.4.2 Liquid Biopsy: Asia Pacific Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
8.5 Others
8.5.1 Overview
8.5.2 Others: Asia Pacific Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Lung Cancer Screening Market Analysis – by Age Group
9.1 Overview
9.2 & Older
9.2.1 Overview
9.2.2 & Older: Australia Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
9.3 Below 50
9.3.1 Overview
9.3.2 Below 50: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Lung Cancer Screening Market Analysis – by End User
10.1 Overview
10.2 Hospitals
10.2.1 Overview
10.2.2 Hospitals: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10.3 Diagnostic Centers
10.3.1 Overview
10.3.2 Diagnostic Centers: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
10.4 Others
10.4.1 Overview
10.4.2 Others: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
11. Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2028 – Country Analysis
11.1 Asia Pacific Lung Cancer Screening Market
11.1.1.1 China: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.1 Overview
11.1.1.1.2 China: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.3 China: Asia Pacific Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.1.4 China: Asia Pacific Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.1.5 China: Asia Pacific Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.1.6 China: Asia Pacific Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.2 Japan: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.1 Overview
11.1.1.2.2 Japan: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.3 Japan: Asia Pacific Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.2.4 Japan: Asia Pacific Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.2.5 Japan: Asia Pacific Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.2.6 Japan: Asia Pacific Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.3 India: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.1 Overview
11.1.1.3.2 India: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.3 India: Asia Pacific Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.3.4 India: Asia Pacific Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.3.5 India: Asia Pacific Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.3.6 India: Asia Pacific Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.4 Australia: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.4.1 Overview
11.1.1.4.2 Australia: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.4.3 Australia: Asia Pacific Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.4.4 Australia: Asia Pacific Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.4.5 Australia: Asia Pacific Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.4.6 Australia: Asia Pacific Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.5 South Korea: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.5.1 Overview
11.1.1.5.2 South Korea: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.5.3 South Korea: Asia Pacific Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.5.4 South Korea: Asia Pacific Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.5.5 South Korea: Asia Pacific Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.5.6 South Korea: Asia Pacific Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
11.1.1.6 Rest of Asia Pacific: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.6.1 Overview
11.1.1.6.2 Rest of Asia Pacific: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
11.1.1.6.3 Rest of Asia Pacific: Asia Pacific Lung Cancer Screening Market, by Cancer Type, 2020-2030 (US$ Million)
11.1.1.6.4 Rest of Asia Pacific: Asia Pacific Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
11.1.1.6.5 Rest of Asia Pacific: Asia Pacific Lung Cancer Screening Market, by Age Group, 2020-2030 (US$ Million)
11.1.1.6.6 Rest of Asia Pacific: Asia Pacific Lung Cancer Screening Market, by End User, 2020-2030 (US$ Million)
12. Asia Pacific Lung Cancer Screening Market–Industry Landscape
12.1 Recent Growth Strategies
12.1.1 Overview
13. Company Profiles
13.1 Intelerad Medical Systems
13.1.1 Key Facts
13.1.2 Business Description
13.1.3 Products and Services
13.1.4 Financial Overview
13.1.5 SWOT Analysis
13.1.6 Key Developments
13.2 Nuance Communications Inc
13.2.1 Key Facts
13.2.2 Business Description
13.2.3 Products and Services
13.2.4 Financial Overview
13.2.5 SWOT Analysis
13.2.6 Key Developments
13.3 GE HealthCare
13.3.1 Key Facts
13.3.2 Business Description
13.3.3 Products and Services
13.3.4 Financial Overview
13.3.5 SWOT Analysis
13.3.6 Key Developments
13.4 Medtronic
13.4.1 Key Facts
13.4.2 Business Description
13.4.3 Products and Services
13.4.4 Financial Overview
13.4.5 SWOT Analysis
13.4.6 Key Developments
13.5 Canon Inc.
13.5.1 Key Facts
13.5.2 Business Description
13.5.3 Products and Services
13.5.4 Financial Overview
13.5.5 SWOT Analysis
13.5.6 Key Developments
13.6 Koninklijke Philips NV
13.6.1 Key Facts
13.6.2 Business Description
13.6.3 Products and Services
13.6.4 Financial Overview
13.6.5 SWOT Analysis
13.6.6 Key Developments
13.7 Siemens AG
13.7.1 Key Facts
13.7.2 Business Description
13.7.3 Products and Services
13.7.4 Financial Overview
13.7.5 SWOT Analysis
13.7.6 Key Developments
14. Appendix
14.1 About
14.2 Glossary of Terms

LIST OF TABLES

Table 1. China: Asia Pacific Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 2. China: Asia Pacific Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 3. China: Asia Pacific Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 4. China: Asia Pacific Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 5. Japan: Asia Pacific Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 6. Japan: Asia Pacific Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 7. Japan: Asia Pacific Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 8. Japan: Asia Pacific Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 9. India: Asia Pacific Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 10. India: Asia Pacific Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 11. India: Asia Pacific Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 12. India: Asia Pacific Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 13. Australia: Asia Pacific Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 14. Australia: Asia Pacific Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 15. Australia: Asia Pacific Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 16. Australia: Asia Pacific Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 17. South Korea: Asia Pacific Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 18. South Korea: Asia Pacific Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 19. South Korea: Asia Pacific Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 20. South Korea: Asia Pacific Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 21. Rest of Asia Pacific Lung Cancer Screening Market, by Cancer Type – Revenue and Forecast to 20228 (US$ Million)
Table 22. Rest of Asia Pacific Lung Cancer Screening Market, by Technology – Revenue and Forecast to 2030 (US$ Million)
Table 23. Rest of Asia Pacific Lung Cancer Screening Market, by Age Group – Revenue and Forecast to 2030 (US$ Million)
Table 24. Rest of Asia Pacific Lung Cancer Screening Market, by End User – Revenue and Forecast to 2030 (US$ Million)
Table 25. Recent Growth Strategies in the Asia Pacific Lung Cancer Screening Market
Table 26. Glossary of Terms

LIST OF FIGURES

Figure 1. Asia Pacific Lung Cancer Screening Market Segmentation
Figure 2. Asia Pacific Lung Cancer Screening Market, by Country
Figure 3. Asia Pacific Lung Cancer Screening Market Overview
Figure 4. Non-Small Cell Lung Cancer Segment Held Largest Share of Cancer Type Segment in Asia Pacific Lung Cancer Screening Market
Figure 5. Asia Pacific Expected to Show Remarkable Growth During Forecast Period
Figure 6. Asia Pacific: PEST Analysis
Figure 7. Experts’ Opinion
Figure 8. Asia Pacific Lung Cancer Screening Market Impact Analysis of Driver and Restraints
Figure 9. Asia Pacific Lung Cancer Screening Market – Revenue Forecast and Analysis – 2020-2030
Figure 10. Asia Pacific Lung Cancer Screening Market Revenue Share, by Cancer Type 2022 & 2030 (%)
Figure 11. Non–Small Cell Lung Cancer (NSCLC): Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Small Cell Lung Cancer: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Asia Pacific Lung Cancer Screening Market, by Technology, 2022 & 2030 (%)
Figure 14. Low-Dose Computed Tomography (LDCT): Asia Pacific Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
Figure 15. Chest X-ray: Asia Pacific Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
Figure 16. Liquid Biopsy: Asia Pacific Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Asia Pacific Lung Cancer Screening Market– Revenue and Forecast to 2030 (US$ Million)
Figure 18. Asia Pacific Lung Cancer Screening Market, by Age group, 2022 & 2030 (%)
Figure 19. 50 & Older: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Below 50: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Asia Pacific Lung Cancer Screening Market, by End User, 2022 & 2030 (%)
Figure 22. Hospitals: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Diagnostic Centers: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Others: Lung Cancer Screenings Market – Revenue and Forecast to 2030 (US$ Million)
Figure 25. Asia Pacific Lung Cancer Screening Market, by Key Country – Revenue (2022) (US$ Million)
Figure 26. Asia Pacific Lung Cancer Screening Market Revenue Share, by Country, 2022 & 2030 (%)
Figure 27. China: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 28. Japan: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 29. India: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 30. Australia: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 31. South Korea: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)
Figure 32. Rest of Asia Pacific: Asia Pacific Lung Cancer Screening Market – Revenue and Forecast to 2030 (US$ Million)

The List of Companies – Asia Pacific Lung Cancer Screening Market

– Intelerad Medical Systems Incorporated
– Nuance Communications Inc
– GE HealthCare Technologies Inc
– Medtronic Plc
– Canon Medical Systems Corp
– Koninklijke Philips NV
– Siemens AG

Reviews

There are no reviews yet.

Be the first to review “Asia Pacific Lung Cancer Screening Market Forecast to 2030”